02 September 2022 | News
Juniper Biologics signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA (chlormethine)
Image credit: shutterstock
Swiss firm Helsinn Group and Singapore's Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, have announced the signing of an exclusive distribution license and supply agreement to register, distribute, promote, market and sell LEDAGA (chlormethine gel) in Australia, Asia and the Middle East as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adults.
Chlormethine gel 0.016%, also known as mechlorethamine gel, is approved in multiple countries, including the EU and US, and is marketed under the trade names LEDAGA and VALCHLOR. The authorized use for each country varies based on the design of the registrational trial and the individual health authority requirements.